NCT05786105Completed
Optical Genome Mapping in Characterization of Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 13 Mar 2024
Brief summary (registry, in English)
The current cytogenetic characterization of Multiple Myeloma (including chromosome and gene abnormalities identification in abnormal plasma cells) encounters some limitations. Indeed current techniques only enable to analyze a limited numbers of predefined abnormalities. New tools that will allow for characterization of abnormalities involved in multiple myeloma development are thus required. The interest of Optical Genome Mapping has already been demonstrated in other hematological diseases. The present study aims at validating Optical Genome Mapping in genetic abnormalities identification for patients with Multiple Myeloma (MM).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 8 (actual)
- First submitted
- 15 Mar 2023
- Start date
- 21 Apr 2023
- Primary completion date
- 21 Nov 2023
- Lead sponsor
- Institut de cancérologie Strasbourg Europe
- Diseases
- Multiple myeloma
- NCT number
- NCT05786105
What you commit to
- Study type: Observational
- Participants enrolled: 8
- From 21 Apr 2023 to the primary completion date, 21 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous treatment of multiple myeloma (except with corticosteroids)
Other illness
- Failure of myelogram
- Failure of FISH
Other
- Opposition of the patient
- Minor or patients placed under guardianship or supervision
- Patients deprived of liberty
- Patients placed under judicial protection
- Patients that are not able to express their consent
- Pregnant and breastfeeding women
Who the study is looking for
- Age ≥ 18 years
- Non previously treated Multiple Myeloma (criteria from the International Myeloma Working Group)
- Presence of CRAB criteria (Calcium Renal Anemia Bone : Calcemia \> 2.75 mmol/l or \> 0.25 mmol/l higher than the Upper Limit of Normal ; serum creatinine \> 173 μmol/l or creatinine clearance \< 40ml per minute attributed to myeloma ; anemia with hemoglobin value \< 10g/dl or more than 2g/dl below the Lower Limit of Normal, bone lesions with osteolytic lesions or osteoporotic vertebral collapses attributed to myeloma)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut de Cancérologie Strasbourg Europe Coordinator of this site? Confirm its status | Strasbourg | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.